Odevixibat
Brand names: Bylvay
Odevixibat is an ileal bile acid transporter inhibitor used to treat cholestatic pruritus in progressive familial intrahepatic cholestasis.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It selectively inhibits the ileal bile acid transporter, reducing reabsorption of bile acids from the terminal ileum and thereby lowering circulating bile acid levels that contribute to pruritus.
Prescribing in practice
- Diarrhoea and disturbances in liver biochemistry are recognised effects, so liver function and fat-soluble vitamin status should be assessed during treatment.
- It is given orally and, in young children, can be administered with food as set out in the prescribing information.
- Interrupt or adjust treatment if there is a significant rise in liver enzymes or persistent diarrhoea.
Monitoring
Monitor liver function tests, serum bile acids and fat-soluble vitamin levels, and review growth and hydration in children.
Counselling the patient
- Advise families that loose stools can occur and to report persistent diarrhoea or signs of dehydration.
- Explain that the medicine aims to relieve itching and that regular blood tests are needed.
Evidence & guidelines
Odevixibat is used for cholestatic pruritus in progressive familial intrahepatic cholestasis in line with its licensed indication and specialist hepatology practice.
Reference: NICE; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Corrected Sodium (Hyperglycaemia) · Electrolytes
- Hyponatraemia Cause Algorithm · Electrolyte Disorders
- MELD-Na Score · Liver Disease
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021